Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 23, 2024PharmacoEconomics - OpenOpen Access

Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story

View Full Paper
Ask AI
Bookmark
Share

Authors

STShe Hui TanLGLouise Gek Huang GohBOBenjamin Shao Kiat Ong

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tan et al. (2024) studied this question.

synapsesocial.com/papers/68e5f515b6db643587589d3dhttps://doi.org/10.1007/s41669-024-00491-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting2019 · 31 citations
  2. 2Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?2020 · 57 citations
  3. 3The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA2020 · 89 citations
  4. 4Policies for biosimilar uptake in Europe: An overview2017 · 358 citations
  5. 5Clinical and Regulatory Concerns of Biosimilars: A Review of Literature2020 · 61 citations